Skip to content

Embecta Corp. EMBC Accrued sales returns

Accrued sales returns at other companies

Halozyme Therapeutics logo
Halozyme TherapeuticsHALO

Other financials

Income statement

See full
Revenue$221.8M-14.4%
Gross profit$127.8M-22.1%
Operating income$35.0M-44.4%
Net income-$4.1M-117%
EPS (diluted)-$0.07-118%

Balance sheet

See full
Cash & equivalents$193.4M-8.9%
Total debt$1.4B-12.5%
Total equity-$626.1M+15.0%
Total assets$1.0B-8.1%

Cash flow

See full
Operating cash flow$31.1M-2.2%
CapEx$500.0K+400%
Free cash flow$30.6M-3.5%

Valuation

See full
Market cap$193.41M-64.3%
Enterprise value$1.37B-24.8%
P/E1.7×-4.8×
P/S0.2×-0.3×

Profitability

See full
Gross margin61.9%-1.6pp
Operating margin25.8%+9.7pp
Net margin10.7%+5.8pp
FCF margin19.6%+16.0pp

Returns & leverage

See full
Return on equity71.9%
Debt / equity
Current ratio2.5×0.0×

Where this comes from

Reported directly by Embecta Corp. in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerRefundLiability.

The official record: Embecta Corp.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Embecta Corp.'s accrued sales returns.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Embecta Corp.'s accrued sales returns?
Embecta Corp. (EMBC) reported accrued sales returns of $126.2M in Q1 2026.
How has Embecta Corp.'s accrued sales returns changed year-over-year?
Embecta Corp.'s accrued sales returns decreased by 1.7% year-over-year, from $128.4M to $126.2M.
What is the long-term trend for Embecta Corp.'s accrued sales returns?
Over 4 years (2021 to 2025), Embecta Corp.'s accrued sales returns has grown at a 12.2% compound annual growth rate (CAGR), from $71.7M to $113.7M.